JP2023528804A - コロナウイルスが引き起こす急性呼吸窮迫症候群(ards)および炎症性障害を処置するための組成物および方法 - Google Patents

コロナウイルスが引き起こす急性呼吸窮迫症候群(ards)および炎症性障害を処置するための組成物および方法 Download PDF

Info

Publication number
JP2023528804A
JP2023528804A JP2022573211A JP2022573211A JP2023528804A JP 2023528804 A JP2023528804 A JP 2023528804A JP 2022573211 A JP2022573211 A JP 2022573211A JP 2022573211 A JP2022573211 A JP 2022573211A JP 2023528804 A JP2023528804 A JP 2023528804A
Authority
JP
Japan
Prior art keywords
sars
drug
cov
inflammatory
ards
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528804A5 (cg-RX-API-DMAC7.html
Inventor
リチャード エル. チャン
ベン ワイ. チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2023528804A publication Critical patent/JP2023528804A/ja
Publication of JP2023528804A5 publication Critical patent/JP2023528804A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022573211A 2020-05-28 2021-05-27 コロナウイルスが引き起こす急性呼吸窮迫症候群(ards)および炎症性障害を処置するための組成物および方法 Pending JP2023528804A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031551P 2020-05-28 2020-05-28
US63/031,551 2020-05-28
PCT/US2021/034494 WO2021243007A2 (en) 2020-05-28 2021-05-27 Compositions and methods for treating acute respiratory distress syndrome (ards) and inflammatory disorders caused by coronaviruses and other respiratory pathogens or agents that mediate pulmonary injury, inflammation or acute respiratory distress, and related compositions and methods for treating and preventing human sars coronavirus infection, covid-19 disease and related symptoms

Publications (2)

Publication Number Publication Date
JP2023528804A true JP2023528804A (ja) 2023-07-06
JP2023528804A5 JP2023528804A5 (cg-RX-API-DMAC7.html) 2025-02-20

Family

ID=78722786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573211A Pending JP2023528804A (ja) 2020-05-28 2021-05-27 コロナウイルスが引き起こす急性呼吸窮迫症候群(ards)および炎症性障害を処置するための組成物および方法

Country Status (12)

Country Link
US (3) US20230248684A1 (cg-RX-API-DMAC7.html)
EP (1) EP4304570A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023528804A (cg-RX-API-DMAC7.html)
KR (1) KR20230058014A (cg-RX-API-DMAC7.html)
CN (1) CN117015375A (cg-RX-API-DMAC7.html)
AU (1) AU2021281257A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024226A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180577A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003348A1 (cg-RX-API-DMAC7.html)
IL (1) IL298593B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022014958A (cg-RX-API-DMAC7.html)
WO (1) WO2021243007A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2021207497A1 (en) * 2020-04-08 2021-10-14 Arizona Board Of Regents On Behalf Of Arizona State University Covid-19 inflammatory cytokine storm treatment
US20230071393A1 (en) * 2020-04-16 2023-03-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Matrix bound vesicles (mbv) for treatment of acute respiratory distress syndrome
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist
CN115252760B (zh) * 2022-03-30 2024-05-31 厦门大学 一种广谱抗冠状病毒的制剂及其制备方法
WO2025029797A1 (en) * 2023-08-01 2025-02-06 Incelldx, Inc. Methods of assigning a covid pathological type and compositions for practicing the same, and methods of treating a subject for chronic covid-19
CN117304031A (zh) * 2023-09-05 2023-12-29 深圳大学 一种铁苋菜二萜类化合物、铁苋菜提取物及其在制备具有抗氧化和/或抗炎作用的产品中的应用
CN117414438B (zh) * 2023-11-01 2025-10-17 大连医科大学附属第一医院 一种靶向m1型巨噬细胞的多肽偶联药物及其应用
CN117919385B (zh) * 2024-02-05 2024-10-18 中国医学科学院医学实验动物研究所 IL-37在MERS-CoV感染疾病的治疗中的应用
CN121490288A (zh) * 2025-11-21 2026-02-10 中山大学附属第三医院 一种用于急性呼吸窘迫综合征的肺部交感神经局部光遗传激活系统及方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155932A2 (en) * 2008-06-25 2009-12-30 H. Lundbeck A/S Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
US20140364492A1 (en) * 2011-10-26 2014-12-11 Korea Research Institute Of Bioscience And Biotechnology Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same
JP2017178890A (ja) * 2016-03-31 2017-10-05 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
US20030109486A1 (en) * 2001-10-31 2003-06-12 Eliezer Rapaport Methods and therapeutic compositions for utilization of adenosine 5'-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155932A2 (en) * 2008-06-25 2009-12-30 H. Lundbeck A/S Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
US20140364492A1 (en) * 2011-10-26 2014-12-11 Korea Research Institute Of Bioscience And Biotechnology Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same
JP2017178890A (ja) * 2016-03-31 2017-10-05 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント

Also Published As

Publication number Publication date
CL2022003348A1 (es) 2023-12-01
BR112022024226A2 (pt) 2023-01-31
CA3180577A1 (en) 2021-12-02
MX2022014958A (es) 2023-04-13
EP4304570A2 (en) 2024-01-17
AU2021281257A1 (en) 2023-02-02
CN117015375A (zh) 2023-11-07
US20240082202A1 (en) 2024-03-14
WO2021243007A2 (en) 2021-12-02
WO2021243007A3 (en) 2021-12-30
US20260041660A1 (en) 2026-02-12
IL298593A (en) 2023-01-01
EP4304570A4 (en) 2025-01-22
KR20230058014A (ko) 2023-05-02
US20230248684A1 (en) 2023-08-10
IL298593B1 (en) 2026-06-01

Similar Documents

Publication Publication Date Title
KR20230058014A (ko) 급성 호흡곤란 증후군(arda) 및 코로나바이러스로 인한 염증 장애를 치료하기 위한 조성물 및 방법
Perico et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Saavedra et al. Immune response during hantavirus diseases: implications for immunotherapies and vaccine design
Panahi et al. An overview on the treatments and prevention against COVID-19
Arvin et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Liu et al. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection
Anand et al. Potential therapeutic targets and vaccine development for SARS-CoV-2/COVID-19 pandemic management: a review on the recent update
TW202144383A (zh) 冠狀病毒免疫原性組合物及其等之用途
Ross et al. Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice
WO2021161043A1 (en) Prevention and treatment of infections including those caused by coronavirus
Song et al. C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury
Lin et al. Coronavirus in human diseases: mechanisms and advances in clinical treatment
Harne et al. SARS-CoV-2 infection and immune responses
Ohadian Moghadam A review on currently available potential therapeutic options for COVID-19
KR20240137110A (ko) 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법
JP2023517920A (ja) コロナウイルス感染の治療
CN111163792A (zh) 用于治疗病毒感染的肽
JP2023529124A (ja) コロナウイルスワクチンコンストラクトおよびこれを作製し使用する方法
US9872895B2 (en) TLR5 ligands, therapeutic methods, and compositions related thereto
JP2024505249A (ja) キメラアデノウイルスベクター
You et al. COVID-19 and lung involvement
US20230355725A1 (en) Neil2 protein therapy for treatment of viral infection
US20250205268A1 (en) Treatment of viruses with antiviral nucleosides
Sojati Type III Interferon-Mediated Responses in Upper and Lower Respiratory Tracts During Infection with Human Metapneumovirus Clinical Isolates
Wang et al. Roles of Human Respiratory Syncytial Virus Proteins in Immune Responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260302